Video

Dr. Gentzler on the Role of Chemotherapy in Metastatic NSCLC

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses the role of chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC).

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses the role of chemotherapy in patients with metastatic non—small cell lung cancer (NSCLC).

Through the identification of different oncogenic drivers and development of targeted therapies, physicians have been able to delay the need for chemotherapy in patients with lung adenocarcinoma, explains Gentzler. Additionally, the use of immunotherapy has proven effective in smokers and patients who do not harbor oncogenic drivers.

Over the past year, data have shown that chemotherapy still has an important role in the treatment paradigm, says Gentzler. When physicians add chemotherapy to an immunotherapy regimen, it seems to show a better chance of response or a longer duration of response. Several studies have looked at chemotherapy as a backbone with immunotherapy. That combination has improved upfront responses, lengthened progression-free survival, and helped patients live longer. Now, trials are showing overall survival improvement by adding PD-1/PD-L1 inhibitors to standard chemotherapy, states Gentzler.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis